c-Myc Antibody (MYC909), Novus Biologicals™

c-Myc

0.2mg/mL

Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

Unconjugated

Mouse

Autophagy, Cancer, Cancer Stem Cells, Cell Cycle and Replication, Chromatin Research, Core ESC Like Genes, Epitope Tags, Myc Epitope Tags, Stem Cell Markers, Transcription Factors and Regulators, Tumor Suppressors

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

4609

Recombinant human c-myc protein

Primary

Store at 4C.

MYC909

Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 1 - 2 ug/ml, Immunofluorescence 1 - 2 ug/ml

Monoclonal

Purified

RUO

Human

avian myelocytomatosis viral oncogene homolog, BHLHE39, bHLHe39MRTL, Class E basic helix-loop-helix protein 39, c-Myc, MYC, myc proto-oncogene protein, MYCC, myc-related translation/localization regulatory factor, Proto-oncogene c-Myc, Transcription factor p64, v-myc avian myelocytomatosis viral oncogene homolog, v-myc myelocytomatosis viral oncogene homolog (avian)

MYC

IgG1 κ

Protein A or G purified

It recognizes a transcription factor of 64-67kDa, identified as c-myc. This MAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or over-expressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. Rearrangement of the MYC gene is found in 3% to 16% of diffuse large B-cell lymphoma (DLBCLs) and in nearly 100% of Burkitt lymphomas (BL). Identifying MYC status is important in establishing final diagnosis of DLBCL, BL, or B-cell lymphoma, with features intermediate between DLBCL and BL as well as in differential diagnoses of the lymphomas.